+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-positive patients



Abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-positive patients



Aids 16(14): 1981




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 034336101

Download citation: RISBibTeXText

PMID: 12351966


Related references

Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. Aids 15(12): 1517-1526, 2001

Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy. Aids 17(12): 1855-1856, 2003

Abacavir based triple nucleoside analogues versus protease inhibitor containing regimens in antiretroviral naive patients with a CD4 count of less than 100 and/or AIDS Observational data from the Frankfurt cohort. AIDS 14(Suppl. 4): S33, 2000

In vivo cell-mediated immunity in subjects with undetectable viral load on protease inhibitor-based versus non-protease inhibitor-based highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 32(5): 570-572, 2003

Relapse of Kaposi's sarcoma in HIV-infected patients switching from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy regimen. Aids 17(10): 1580-1581, 2003

Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies. Aids 17(18): 2629-2634, 2003

Differential CD4 T-cell response in HIV-1-infected patients using protease inhibitor-based or nevirapine-based highly active antiretroviral therapy. HIV Medicine 5(2): 74-81, 2004

Non Protease Inhibitor-Based Highly Active Antiretroviral Therapy (HAART) improves micromineral status in HIV positive Nigerians. Nigerian Journal of Physiological Sciences 28(1): 105-107, 2013

Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. HIV Medicine 10(9): 527-535, 2009

Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy. HIV Medicine 7(5): 311-316, 2006

Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clinical Infectious Diseases 41(9): 1326-1332, 2005

Switch to abacavir-based triple nucleoside regimens in HIV-1 infected patients never treated with suboptimal antiretroviral therapy: a review. Medical Science Monitor 12(12): Ra269-Ra276, 2006

Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Lancet 368(9546): 1503-1515, 2006

Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses. Yearbook of Dermatology and Dermatologic Surgery 2007: 155-156, 2007

Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. Aids 17(17): 2451-2459, 2003